EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property
...t diseases of the central nervous system and lung conditions. In addition, epix
has programs related to its MRI imaging business. epix
also has collaborations with several leading pharmaceutical and research fo...
EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
...., C.P.A. ("Finn"), announced today that assets of epix
Pharmaceuticals, Inc. ("EPIX") have been assigned ... nervous system and lung conditions. In addition, epix
has several programs related to its MRI imaging bu...adofosveset trisodium, by Bayer Schering Pharma.) epix
also has collaborations with several leading pharm...
New Immune Approach for Treatment of Alzheimer's Disease
...ress in Philadelphia on June 10 and 11. On the second day of this conference, after presentations by researchers from Abbott Laboratories, Medivation, epix
Pharmaceuticals, the Buck Institute, Cleveland Clinic, and others, Edward Tobinick MD, Director of the Institute for Neurological Research® (INR&...
Biotech Hot in July Driven by Positive Drug Data and Acquisitions
...f and/or putting promising projects in the refrigerator. Recent announcements included:
- Celera cut 80 employees or 13 percent of its workforce
Pharmaceuticals entered bankruptcy and is winding down its operations.
- YTD the Burrill Biotech Select Index is up 4 percent
2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession
...el Pharma, Anacor Pharmaceuticals, Ceragenix, Millennium Pharmaceuticals (Takeda), Pharmasset, Oscient Pharmaceuticals, Cenomed Biosciences, Alkermes, epix
Pharmaceuticals, and Ardea Biosciences.
The exhibit area is strictly limited to 100 booths and is nearly full 3 1/2 months before the show. The...
Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
...uding PR-047, an oral proteasome inhibitor for the treatment of cancer.
Most recently, Dr. Kauffman was President and Chief Executive Officer of epix
Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.) from 2002 to 2008. From 1997 to 2002, he held a number of senior medical and program ...
Gene Network Sciences Announces Michael Gilman as Board Member
...sity of California, Berkeley , and an S.B. in Life Sciences from Massachusetts Institute of Technology . He also serves on the Board of Directors of epix
"Michael Gilman's broad pharma research leadership experience will play a critical role in GNS's effectively deploying our ...
Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
and depth of sector knowledge will be of tremendous value to both the firm and
Mr. Webb was previously President & CEO of epix
Pharmaceuticals where he
completed over $225 million in financings, including its 1997 IPO, and raised
an additional $150 million through corporate pa...
Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
...zyme Corporation and Vice President of Baxter Travenol Laboratories, Inc
(now Baxter Healthcare). Mr. Phelps is currently on the Board of Directors
Pharmaceuticals and has previously served on the Boards of
Directors of nine public and private companies in the health care field, as
well as on the ...
BioVascular, Inc. Expands Executive Team
...o Eli Lilly for $315M; Novacardia, sold to Merck
for $350M; Predix, sold to epix
Medical; and Adiana, sold to Cytyc. Prior
to working at Forward Ventures, M...pinski held business development and
strategic planning roles at Genentech, epix
Medical and the pharmaceutical
consulting practice of Arthur D. Little. Mr....
New Report Analyzes Key Controversies in Multiple Sclerosis Treatment
...MAb. Drugs/Mechanisms mentioned in this report include: S1P agonists
(fingolimod; Novartis, S1P1; Roche/Actelion, Sphingomab; Lpath, S1P1
/ Amgen), inhibitors of DNA synthesis/repair
(teriflunomide; Sanofi-Aventis, cladribine; Ivax/Serono), potassium channel
blockers (fampridine; Acorda,...